Isavuconazole for invasive mold disease in patients with hematological malignancies: a multicenter real-world study from China on efficacy, safety, and competing risks. (PubMed, Antimicrob Agents Chemother) - Jul 7, 2026 - "In this real-world Chinese cohort, isavuconazole achieved 59.5% treatment success with favorable safety. Infection type and treatment strategy were key prognostic factors: aspergillosis and monotherapy were associated with better outcomes, whereas mucormycosis and combination therapy were associated with higher attributable mortality risk."
Journal • Real-world evidence • Hematological Disorders • Hematological Malignancies • Infectious Disease • Oncology • Pulmonary Disease • Respiratory Diseases
|
|
Hui Wang; Jiaojiao Mao; Jingjing Ma; Jirui Zhang; Mengying Xu
|